IDEAYA Biosciences and Servier to present darovasertib data from three trials at ESMO 2026

IDEAYA Biosciences and Servier announced data from three clinical trials at ESMO 2026 supporting the potential of darovasertib as a foundational new therapy for patients across the treatment journey of uveal melanoma.

Detected & updated continuously · Source: Nebula